What's breaking now, across thousands of outlets.
Novo views the medicine, acquired in a billion-dollar deal, as a future blockbuster. Meanwhile, a pair of startups forged an RNA editing pact and Astellas lined up two new trials in pancreatic cancer.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
A deal for smart-ring maker Oura to acquire a telehealth company is raising conflict-of-interest questions for Eli Lilly
(MedPage Today) -- Shifting gears on prostate cancer screening, the American Cancer Society (ACS) now recommends screening with prostate-specific antigen (PSA) every 2 years for average-risk men ages…
Scientists have long known that regular exercise decreases the risk of developing many types of cancer. But last year, results from a large, randomized clinical trial of patients with colon cancer…
The findings from researchers at Columbia University and NYU challenge conventional thinking about weight and health.
When doctors find a blockage in a patient's heart arteries, a common treatment option is a procedure to open the artery and restore blood flow.
